5-Amino-1MQ: NNMT Inhibition, Metabolic Research and Evidence Limits
5-Amino-1MQ is a small-molecule research compound investigated as an inhibitor of nicotinamide N-methyltransferase, usually shortened to NNMT. It is not a peptide. The directly checked studies below concern cells and obese mice, not a demonstrated weight-loss treatment for people. Its scientific interest comes from a metabolic target, rather than from evidence that a commercially available product produces predictable human results. Original discovery study.
The evidence in one view
Identity
Small molecule studied against NNMT. Inclusion in a peptide library does not change its chemical class.
Evidence level
The selected efficacy experiments are preclinical. Mouse metabolic outcomes are the relevant observations.
Unresolved question
These experiments do not establish a human dose, lasting weight reduction or a human safety margin.
This profile evaluates what the research can support. It does not supply a personal dosing schedule. Treat the study summaries as a map of specific experiments and use the linked originals to inspect their methods.
What NNMT inhibition means
The initial investigation tested methylquinolinium compounds for membrane permeability and enzyme inhibition. In cultured fat cells, NNMT inhibition changed nicotinamide-related metabolism, including lower 1-methylnicotinamide and higher NAD+ and S-adenosylmethionine. The authors also reported suppression of lipid synthesis. These are biochemical and cellular findings, not measurements of a person’s energy, appetite or health span. Discovery paper.
An appropriate interpretation separates three questions. Does the compound reach its intended target? Does changing that target alter a disease-relevant outcome? Does the overall balance of benefits and harms favor treatment in people? A positive answer to the first question cannot stand in for the other two. In particular, a change in NAD+ should not be silently translated into an anti-aging claim.
What the individual studies found
Early obese-mouse experiments
The discovery report described lower body weight, white fat mass, fat-cell size and cholesterol in treated diet-induced obese mice. Food intake did not explain the reported effect. The authors did not observe adverse effects in that experimental setting. That last finding is bounded by the animals, exposure and observations in the study; it is not an established human safety profile. Original report.
A diet-combination experiment
Sampson and colleagues studied an NNMT inhibitor alongside a switch from a high-fat diet to a lean diet. The combination produced greater improvements in body weight, fat mass and liver fat than the diet switch alone in obese mice. The analysis also described an increased ratio of lean mass to total body weight and changes in adipose-tissue metabolites. 2021 study.
Two interpretation rules matter here. First, retain the dietary intervention when describing a combination experiment. Calling this simply a drug-induced transformation removes a material part of the comparison. Second, an increased lean-mass proportion does not by itself demonstrate new muscle growth. A ratio may improve because its denominator falls. A muscle-building claim would require the appropriate absolute measurements and a study designed to evaluate that outcome.
A later metabolic-dysfunction study
A 2024 report found that 5-Amino-1MQ limited weight and fat-mass gain in obese mice and improved measures related to glucose regulation and liver fat. The study also investigated drug exposure across tissues and routes. Its screening identified activity against MAO-A, an additional pharmacological consideration beyond NNMT. The authors disclosed commercial relationships involving Ridgeline Therapeutics. 2024 original study.
Use “limited gain” when that is the result. It is not interchangeable with weight loss from baseline. Commercial disclosures should be visible because they help readers assess the research context; they do not, by themselves, invalidate a result. Independent replication and detailed methods remain more useful than either dismissing an industry-linked paper or accepting it uncritically.
Claims that need separate evidence
| Claim a reader may encounter | What to ask before accepting it |
|---|---|
| “Burns fat without changing lifestyle” | Was that exact claim tested in people, with a suitable comparison and measured adherence? |
| “Raises NAD+, therefore slows aging” | Where is the clinical aging outcome, rather than an intermediate biochemical measurement? |
| “Preserves or builds muscle” | Were absolute muscle mass, strength and function measured, or only a body-composition ratio? |
| “Highly selective means safe” | Were relevant off-target effects and exposure-dependent harms evaluated? |
| “Works orally” | Is there human absorption and exposure evidence for the actual formulation? |
These are evidence requirements, not claims that a particular benefit is impossible. An uncertainty should remain an uncertainty until the relevant experiment resolves it. For a broader explanation, see why molecular identity matters.
Safety questions deserve their own assessment
The MAO-A signal in the 2024 screening is a reason to avoid describing this compound as pharmacologically confined to NNMT. It does not establish the size of a drug interaction in a person or identify a safe combination with another substance. Those conclusions would require their own exposure and clinical data. Pharmacology and screening report.
Do not create a safety protocol by assembling anecdotes about blood pressure, laboratory tests or supplement combinations. A monitoring suggestion is not validation of an intervention. Similarly, a short experiment without an observed problem cannot answer a long-duration exposure question that it did not test.
For a research assessment, request the chemical identity, counterion or salt specification, actual assay methods and lot-linked results. Keep identity testing separate from biological safety. An accurate label would address what is in a sample; it would not establish what repeated exposure does to a person. The purity and certificate-of-analysis guide explains the distinction.
Why a mouse dose is not a consumer protocol
The useful question is not simply how to convert milligrams by body weight. Before a clinical regimen can be defended, the evidence needs to connect the administered material, route, achieved exposure, target engagement and observed harms. A different formulation can break that chain even when the name on the label looks similar.
This profile therefore does not supply a cycle length, injection plan or combination recommendation. It also does not treat a vendor’s concentration as evidence of efficacy. Those omissions preserve the actual boundary of the checked research rather than turning an experimental signal into an instruction that the studies did not validate.
Frequently asked questions
Is 5-Amino-1MQ the same as NAD+?
No. The research evaluates an NNMT inhibitor, while NAD+ is among the metabolites discussed in relation to the pathway. A pathway connection is not chemical identity. Research on one should not be cited as direct treatment evidence for the other. Discovery study.
Does this establish a human weight-loss percentage?
No human weight-loss percentage can be calculated from the selected mouse efficacy studies. Presenting their relative changes as a forecast for a person would go beyond their designs.
Is less weight gain a failed experiment?
Not necessarily. Evaluate it against the experiment’s prespecified objective. Limiting gain can be a meaningful observation within an obesity model. It still should not be relabeled as reversal of obesity or a demonstrated treatment effect in humans.
What evidence would materially improve confidence?
Prioritize a clearly identified clinical product, human pharmacokinetics, systematic safety reporting and controlled trials with relevant outcomes. Ask for withdrawals and follow-up as well as favorable averages. For research literacy, start with reading a study and interpreting negative findings.
Sources and editorial scope
Sources checked September 21, 2026: the original discovery report, the 2021 diet-combination experiment and the 2024 metabolic-dysfunction paper linked above. This is a focused evidence profile, not a systematic review or a claim that every possible study has been found. Study findings, editorial interpretation and unanswered questions are distinguished throughout.